New research and industry commentary converge on the delivery problem in cell and gene therapy—specifically how improvements to AAV platforms and alternative delivery methods aim to address manufacturing, safety, and tissue targeting constraints. On the science side, reports describe activated T-cell extracellular vesicles carrying DNA that can boost antigen presentation in tumor cells and synergize with immune checkpoint inhibitors, suggesting new “acellular immunotherapy” angles. Separately, broader platform discussions highlight efforts to improve AAV workflows at scale and to advance non-viral gene delivery approaches that can enable repeated dosing and reduce immune barriers, positioning delivery innovation as a core determinant of clinical translation.